Facio presents its business approach at the Dutch Life Sciences Conference

Leiden, the Netherlands - November 17, 2016

Facio Therapies will present its business approach at the Dutch Life Sciences Conference in Leiden, the Netherlands, on November 24th, 2016.

Facio’s single goal is to develop a causal therapy for facioscapulohumeral dystrophy (FSHD), a devastating muscle wasting disease that affects over 700,000 people worldwide. With active support from the global FSHD community, Facio is committed to maximizing the accessibility and affordability of its therapeutics. This calls for a socially responsible business model that will allow the creation of sustainable value for people with FSHD and shareholders alike.

Facio’s Chairman, Kees van der Graaf, will present Facio’s business approach during the Dutch Life Sciences Conference at the ‘ECC Leiden’ in Leiden, the Netherlands, on November 24th , 2016, at 13:30 – 15:00 (CET). Kees, a former member of the executive board of Unilever, co-founded Facio in 2014. Together with his wife, Renée, he also founded the Dutch FSHD Foundation (the FSHD Stichting), which he still chairs.

About FSHD

FSHD (facioscapulohumeral dystrophy) is a skeletal muscle wasting disease that devastates the lives of over 700,000 people worldwide and those close to them. The loss of muscle strength has a huge impact on daily life. Living with FSHD means living with pain, fatigue, and social isolation. Above all, the future becomes uncertain because the course of the disease is unpredictable. About 20% of people with FSHD end up in a wheelchair. Currently, no therapy for FSHD is available other than forms of temporary symptomatic relief.

About Facio Therapies BV

Facio Therapies, established in 2014, is a Netherlands-based company with a single focus: to overcome FSHD by developing a causal therapy that restores the natural repression of the muscle-toxic protein, DUX4. When unduly produced in skeletal muscle, DUX4 sets in motion a cascade of cellular events that eventually result in the muscle wasting seen in FSHD. Facio is the only one in the FSHD field with a fully automated, high-throughput screening platform based on quantifying the DUX4 protein in unadulterated (“primary”) FSHD-affected muscle cells. Facio delivered the first-ever therapeutically relevant proof of principle in FSHD by showing that one of its lead candidates, an orally active small molecule, represses DUX4 levels produced by human FSHD-affected muscle cells in a unique animal model (“in vivo”).

Rooted in, and dedicated to working for the FSHD community, Facio’s business approach is to have a positive impact on lives rather than to maximize financial gain. Since inception, Facio has raised over €16M in equity funding from FSHD-affected families, their friends, FSHD foundations, and Facio’s drug discovery partner, Evotec. Facio’s Board consists of business leaders from the FSHD community – Kees van der Graaf (Chairman; Netherlands), Neil Camarta (Canada), Dave Mackay (USA), Bill Moss (Australia), and Chip Wilson (Canada) – and Evotec’s CSO, Cord Dohrmann (Germany).